Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer

Background Amivantamab is a novel bispecific antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (HGFR/c-MET) that are overexpressed in several types of cancer including triple-negative breast cancer (TNBC). Targeting both recept...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of nuclear medicine and molecular imaging 2021-02, Vol.48 (2), p.383-394
Hauptverfasser:	Cavaliere, Alessandra, Sun, Suxia, Lee, Supum, Bodner, Jacob, Li, Ziqi, Huang, Yiyun, Moores, Sheri L., Marquez-Nostra, Bernadette
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies Binding Bispecific antibodies Breast cancer c-Met protein Cardiology Cell Line, Tumor Cell surface Computed tomography Deferoxamine Diagnostic systems Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - metabolism Growth factors Hepatocyte growth factor Humans Imaging In vivo methods and tests Lung cancer Medical imaging Medicine Medicine & Public Health Mice Monoclonal antibodies Nuclear Medicine Oncology Original Article Orthopedics Positron emission Positron Emission Tomography Computed Tomography Positron-Emission Tomography Preclinical Imaging Proto-Oncogene Proteins c-met Radiochemistry Radioisotopes Radiology Receptors Targeted cancer therapy Tissue Distribution Tomography Triple Negative Breast Neoplasms - diagnostic imaging Tumors Xenografts Xenotransplantation Zirconium Zirconium isotopes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!